{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:19:51Z","timestamp":1763036391203},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/jcp.0b013e318172757f","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:43:21Z","timestamp":1236260601000},"page":"352-353","source":"Crossref","is-referenced-by-count":7,"title":["Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms"],"prefix":"10.1097","volume":"28","author":[{"given":"Enrique","family":"L\u00f3pez-Torres","sequence":"first","affiliation":[]},{"given":"Jes\u00fas","family":"Salom\u00f3n","sequence":"additional","affiliation":[]},{"given":"Francis","family":"Vicario","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Pe\u00f1as-LLed\u00f3","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Dorado","sequence":"additional","affiliation":[]},{"given":"Adri\u00e1n","family":"Llerena","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-18-20210128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.163.1.160-a","article-title":"Aripiprazole-induced movement disorder.","volume":"163","author":"Zacher","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R4-18-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/01.yic.0000185025.40656.30","article-title":"Aripiprazole-induced parkinsonism.","volume":"21","author":"Sharma","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R5-18-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s002280000222","article-title":"CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.","volume":"56","author":"Scordo","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","article-title":"Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.","volume":"63","author":"Guzey","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/1531-8257(200011)15:6<1070::AID-MDS1003>3.0.CO;2-A","article-title":"Allelic association between the DRD2 TaqI A polymorphisms and Parkinson's disease.","volume":"15","author":"Grevle","year":"2000","journal-title":"Mov Disord"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000203200.96205.34","article-title":"Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450, and serotonin and dopamine transporter and receptor polymorphisms.","volume":"26","author":"Hedenmalm","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","article-title":"Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.","volume":"190","author":"Gunes","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.mp.4000847","article-title":"Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.","volume":"6","author":"Basile","year":"2001","journal-title":"Mol Psychiatry"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3282f01aa3","article-title":"CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.","volume":"17","author":"Aklillu","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"R12-18-20210128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200806000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:13:16Z","timestamp":1618035196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200806000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318172757f","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}